This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11160%2F12%3A10124217%21RIV13-MSM-11160___/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11160%2F12%3A10124217%21RIV13-MSM-11160___
rdf:type
n16:Vysledek skos:Concept
rdfs:seeAlso
http://rabbit.if-pan.krakow.pl/pjp/pdf/2012/2_428.pdf
dcterms:description
Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartment was found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivity were absorbed after oral administration. Conclusion: This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments. Background: Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA. Methods: In this study, HYA of different molecular weights (0.1-1 MDa) was labelled with Tc-99m, and the distribution profiles were determined after administrating the HYA to rats. Results: After the intravenous administration of Tc-99m-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of Tc-99m-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of Tc-99m-HYA, no significant absorption to the central compartment was found. A preliminary study using C-14-HYA exhibited a different distribution profile than Tc-99m-HYA because of the different administered dose and the fate of the degradation products. Even with C-14-HYA, only traces of radioactivity were absorbed after oral administration. Conclusion: This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments.
dcterms:title
Preclinical pharmacokinetics of radiolabelled hyaluronan Preclinical pharmacokinetics of radiolabelled hyaluronan
skos:prefLabel
Preclinical pharmacokinetics of radiolabelled hyaluronan Preclinical pharmacokinetics of radiolabelled hyaluronan
skos:notation
RIV/00216208:11160/12:10124217!RIV13-MSM-11160___
n16:predkladatel
n18:orjk%3A11160
n4:aktivita
n10:I
n4:aktivity
I
n4:cisloPeriodika
2
n4:dodaniDat
n9:2013
n4:domaciTvurceVysledku
n12:5940583 n12:9593756 n12:3834409
n4:druhVysledku
n15:J
n4:duvernostUdaju
n7:S
n4:entitaPredkladatele
n19:predkladatel
n4:idSjednocenehoVysledku
160958
n4:idVysledku
RIV/00216208:11160/12:10124217
n4:jazykVysledku
n17:eng
n4:klicovaSlova
pharmacokinetics; biodistribution; radiolabelling; Tc-99m; C-14; hyaluronan
n4:klicoveSlovo
n5:C-14 n5:radiolabelling n5:biodistribution n5:Tc-99m n5:pharmacokinetics n5:hyaluronan
n4:kodStatuVydavatele
PL - Polská republika
n4:kontrolniKodProRIV
[74E56B1939FF]
n4:nazevZdroje
Pharmacological Reports
n4:obor
n11:FR
n4:pocetDomacichTvurcuVysledku
3
n4:pocetTvurcuVysledku
4
n4:rokUplatneniVysledku
n9:2012
n4:svazekPeriodika
64
n4:tvurceVysledku
Lázníčková, Alice Lázníček, Milan Čožíková, Dagmar Velebny, Vladimir
n4:wos
000305546700023
s:issn
1734-1140
s:numberOfPages
10
n14:organizacniJednotka
11160